Drug
resistance in new China bird flu raises concern
The
new bird flu strain that has killed 36 people in China has proved
resistant to Tamiflu for the first time, a development scientists
said was "concerning".
28
May, 2013
The
H7N9 virus was found to be resistant to Roche's widely used flu drug
in three out of 14 patients who were studied in detail by doctors
from Shanghai and Hong Kong.
Tamiflu,
which is given as a pill, belongs to a group of medicines known as
neuraminidase inhibitors that currently offer the only known
treatment option for bird flu. GlaxoSmithKline's inhaled medicine
Relenza has the same mode of action.
In
one patient, the gene mutation responsible for resistance appears to
have arisen after infection took hold, probably as a result of
treatment with Tamiflu, leading to concerns that medication may be
the trigger for resistance to develop.
"The
apparent ease with which antiviral resistance emerges in A/H7N9
viruses is concerning; it needs to be closely monitored and
considered in future pandemic response plans," the researchers
wrote in an article published online by The Lancet medical journal on
Tuesday.
Earlier
genetic studies had raised worries about drug resistance but this is
the first time that the problem has been documented in clinical
cases.
For
most of the 14 patients studied, Tamiflu successfully reduced the
amount of virus found in throat swabs and helped speed clinical
recovery. But it had no impact on the amount of virus found in swabs
from three patients who became severely ill.
A
spokeswoman for Swiss-based drugmaker Roche said rates of Tamiflu
resistance remained low globally, but it took the issue of resistance
"very seriously" and was collaborating with health
authorities to monitor the situation.
The
H7N9 virus is known to have infected 131 people in China since
February, but no new cases have been detected since early May,
according to the World Health Organization.
Experts
from the United Nations agency said last week the bird flu outbreak
in China had caused some $6.5 billion in losses to the economy.
Scientific
studies of the virus have established it is being transmitted from
birds - probably mostly chickens - to people. But experts have yet to
identify the source of the circulating virus - the so-called
"reservoir" - that is leading to chickens contracting it
and sporadically passing it on to humans.
Frenchman
dies of new coronavirus after trip to Dubai
A
Frenchman has died after contracting
a SARS-like virus that
has killed
22 of its 44 known victims,
the Associated Press reported
28
May, 2013
.
The
65-year-old man, whose name has not been made public, was
hospitalized with respiratory symptoms after a trip to Dubai in
mid-April. His hospital roommate also tested positive for the
illness, according to the AP.
The
new virus, dubbed MERS-CoV for Middle East respiratory syndrome
coronavirus, was first identified in September 2012 following the
infections of a Qatari man in a British hospital and a woman who died
in Saudi Arabia. Like its cousin SARS, severe acute respiratory
syndrome, it can cause pneumonia and organ failure. But unlike SARS,
which a decade ago sickened more than 8,000 people and killed 775, it
doesn't appear to spread as easily from person to person.
Although
European countries such as the United Kingdom and France have seen
cases of MERS-CoV, the majority of cases have clustered in the
Arabian Peninsula, according to the U.S.
Centers for Disease Control and Prevention.
"CDC
recommends that U.S. travelers to countries in or near the Arabian
Peninsula monitor their health and see a doctor right away if they
develop fever and symptoms of lower respiratory illness, such as
cough or shortness of breath. They should tell the doctor about their
recent travel," the agency said in a statement.
Saudi
Arabia has seen 32 cases of MERS-CoV, 17 of which were fatal,
according to the
World Health Organization.
The majority of the country's cases stemmed from an outbreak at an
Al-Ahsa health care facility, where 22 patients have been sickened by
the virus and 10 have died.
No comments:
Post a Comment
Note: only a member of this blog may post a comment.